




Supplementary

A



Histology



B






Figure S1 Kaplan-Meier analysis of OS, CSS, and DFS for CB2 tumor tissue gene expression positivity in NSCLC patients with (A) and without adjuvant chemotherapy (B). neg., negative; pos., positive; HR, hazard ratio; OS, overall survival; CSS, cancer specific survival; DFS, disease free survival; CB2, cannabinoid receptor 2; NSCLC, non-small cell lung cancer.

Table S1 Eight multivariate Cox models (stratified by the stage variable and with age and gender as an adjusting variables) analyzing the influence of tested variables CB1 (qRT-PCR), CB1 (IHC), CB2 (qRT-PCR) and CB2 (IHC) on CSS and DFS

Adjusting variables	CB1 gene (qRT-PCR)			CB1 protein (IHC)			CB2 gene (qRT-PCR)			CB2 protein (IHC)		
	HR	95% CI	P value	HR	95% CI	P value	HR	95% CI	P value	HR	95% CI	P value
CSS												
Age	1.101	1.022–1.186	0.011	1.088	1.002–1.181	0.045	1.120	1.037–1.210	0.004	1.089	1.011–1.174	0.025
Gender (male)	0.551	0.195–1.559	0.262	0.517	0.166–1.613	0.256	0.521	0.177–1.532	0.236	0.557	0.188–1.652	0.291
CB positivity	0.508	0.113–2.284	0.377	1.325	0.378–4.635	0.660	0.274	0.099–0.759	0.013	1.261	0.451–3.523	0.658
DFS												
Age	1.032	0.985–1.081	0.179	1.015	0.963–1.071	0.579	1.042	0.995–1.091	0.077	1.017	0.969–1.067	0.499
Gender (male)	0.824	0.359–1.890	0.648	0.715	0.295–1.734	0.457	0.675	0.290–1.571	0.362	0.803	0.346–1.863	0.609
CB positivity	0.418	0.122–1.436	0.166	1.343	0.532–3.389	0.532	0.322	0.137–0.756	0.009	1.331	0.579–3.057	0.501

CB, cannabinoid receptor; qRT-PCR, quantitative reverse-transcriptase polymerase chain reaction; IHC, immunohistochemistry; CSS, cancer specific survival; DFS, disease free survival; HR, hazard ratio; CI, confidence interval;

Table S2 Three multivariate Cox models (stratified by the stage variable and with age and gender as an adjusting variables) analyzing the influence of positivity of *CB2* (qRT-PCR) on CSS and DFS with different adjusting variables weight, BMI and chemotherapy administration

Adjusting variables	CSS			DFS		
	HR	95% CI	P value	HR	95% CI	P value
A						
Age	1.128	1.038–1.227	0.005	1.043	0.996–1.092	0.077
Gender (male)	0.627	0.196–2.006	0.432	0.660	0.264–1.650	0.374
Weight	0.978	0.945–1.013	0.213	1.002	0.974–1.030	0.901
<i>CB2</i> gene qRT-PCR positivity (≤ 1.0)	0.254	0.087–0.744	0.012	0.323	0.137–0.760	0.010
B						
Age	1.123	1.036–1.217	0.005	1.042	0.995–1.092	0.080
Gender (male)	0.527	0.174–1.600	0.258	0.677	0.289–1.582	0.367
BMI	0.957	0.860–1.066	0.425	0.999	0.919–1.085	0.972
<i>CB2</i> gene qRT-PCR positivity (≤ 1.0)	0.268	0.094–0.762	0.014	0.321	0.137–0.756	0.009
C						
Age	1.115	1.033–1.203	0.005	1.041	0.995–1.090	0.084
Gender (male)	0.561	0.189–1.664	0.298	0.707	0.304–1.649	0.423
Chemotherapy yes	0.576	0.150–2.211	0.421	0.602	0.175–2.066	0.420
<i>CB2</i> gene qRT-PCR positivity (≤ 1.0)	0.272	0.099–0.747	0.012	0.317	0.136–0.738	0.008

CB, cannabinoid receptor; qRT-PCR, quantitative reverse-transcriptase polymerase chain reaction; CSS, cancer specific survival; DFS, disease free survival; BMI, body mass index; HR, hazard ratio; CI, confidence interval.

Table S3 Survival parameters of the cohort in months

Stage I–III	N	Events	3-year-survival
OS	98	40 (40.8%)	63.2% \pm 4.9%
CSS	94	21 (22.3%)	78.2% \pm 4.4%
DFS	98	30 (30.6%)	70% \pm 5.2%

N, number; OS, overall survival; CSS, cancer specific survival; DFS, disease free survival.

Table S4 The contingency tables of *CB1* and *CB2* gene (qRT-PCR) and protein (IHC) expressions

Gene and protein expressions	CB1 gene (qRT-PCR)		CB2 gene (qRT-PCR)	
	neg. (>11.2)	pos. (≤ 11.2)	neg. (>1.0)	pos. (≤ 1.0)
CB1 protein (IHC)				
Weak	36	8	–	–
High	20	7	–	–
P value	0.634		–	
CB2 protein (IHC)				
Weak	–	–	6	44
High	–	–	6	17
P value	–		0.176	

CB, cannabinoid receptor; qRT-PCR, quantitative reverse-transcriptase polymerase chain reaction; IHC, immunohistochemistry; neg., negative; pos., positive.